287 related articles for article (PubMed ID: 30728077)
1. Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity.
Miret JJ; Kirschmeier P; Koyama S; Zhu M; Li YY; Naito Y; Wu M; Malladi VS; Huang W; Walker W; Palakurthi S; Dranoff G; Hammerman PS; Pecot CV; Wong KK; Akbay EA
J Immunother Cancer; 2019 Feb; 7(1):32. PubMed ID: 30728077
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment.
Steggerda SM; Bennett MK; Chen J; Emberley E; Huang T; Janes JR; Li W; MacKinnon AL; Makkouk A; Marguier G; Murray PJ; Neou S; Pan A; Parlati F; Rodriguez MLM; Van de Velde LA; Wang T; Works M; Zhang J; Zhang W; Gross MI
J Immunother Cancer; 2017 Dec; 5(1):101. PubMed ID: 29254508
[TBL] [Abstract][Full Text] [Related]
3. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses.
Rodriguez PC; Quiceno DG; Zabaleta J; Ortiz B; Zea AH; Piazuelo MB; Delgado A; Correa P; Brayer J; Sotomayor EM; Antonia S; Ochoa JB; Ochoa AC
Cancer Res; 2004 Aug; 64(16):5839-49. PubMed ID: 15313928
[TBL] [Abstract][Full Text] [Related]
4. Arginase-1 mRNA expression correlates with myeloid-derived suppressor cell levels in peripheral blood of NSCLC patients.
Heuvers ME; Muskens F; Bezemer K; Lambers M; Dingemans AC; Groen HJM; Smit EF; Hoogsteden HC; Hegmans JPJJ; Aerts JGJV
Lung Cancer; 2013 Sep; 81(3):468-474. PubMed ID: 23850196
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Granulocytic Myeloid-Derived Suppressor Cells Overcomes Resistance to Immune Checkpoint Inhibition in LKB1-Deficient Non-Small Cell Lung Cancer.
Li R; Salehi-Rad R; Crosson W; Momcilovic M; Lim RJ; Ong SL; Huang ZL; Zhang T; Abascal J; Dumitras C; Jing Z; Park SJ; Krysan K; Shackelford DB; Tran LM; Liu B; Dubinett SM
Cancer Res; 2021 Jun; 81(12):3295-3308. PubMed ID: 33853830
[TBL] [Abstract][Full Text] [Related]
6. Arginase 2 is expressed by human lung cancer, but it neither induces immune suppression, nor affects disease progression.
Rotondo R; Mastracci L; Piazza T; Barisione G; Fabbi M; Cassanello M; Costa R; Morandi B; Astigiano S; Cesario A; Sormani MP; Ferlazzo G; Grossi F; Ratto GB; Ferrini S; Frumento G
Int J Cancer; 2008 Sep; 123(5):1108-16. PubMed ID: 18528866
[TBL] [Abstract][Full Text] [Related]
7. CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer.
Feng PH; Lee KY; Chang YL; Chan YF; Kuo LW; Lin TY; Chung FT; Kuo CS; Yu CT; Lin SM; Wang CH; Chou CL; Huang CD; Kuo HP
Am J Respir Crit Care Med; 2012 Nov; 186(10):1025-36. PubMed ID: 22955317
[TBL] [Abstract][Full Text] [Related]
8. IL-8 induces exocytosis of arginase 1 by neutrophil polymorphonuclears in nonsmall cell lung cancer.
Rotondo R; Barisione G; Mastracci L; Grossi F; Orengo AM; Costa R; Truini M; Fabbi M; Ferrini S; Barbieri O
Int J Cancer; 2009 Aug; 125(4):887-93. PubMed ID: 19431148
[TBL] [Abstract][Full Text] [Related]
9. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer.
Liu CY; Wang YM; Wang CL; Feng PH; Ko HW; Liu YH; Wu YC; Chu Y; Chung FT; Kuo CH; Lee KY; Lin SM; Lin HC; Wang CH; Yu CT; Kuo HP
J Cancer Res Clin Oncol; 2010 Jan; 136(1):35-45. PubMed ID: 19572148
[TBL] [Abstract][Full Text] [Related]
10. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
[TBL] [Abstract][Full Text] [Related]
11. Novel Kras-mutant murine models of non-small cell lung cancer possessing co-occurring oncogenic mutations and increased tumor mutational burden.
Salehi-Rad R; Li R; Tran LM; Lim RJ; Abascal J; Momcilovic M; Park SJ; Ong SL; Shabihkhani M; Huang ZL; Paul M; Shackelford DB; Krysan K; Liu B; Dubinett SM
Cancer Immunol Immunother; 2021 Aug; 70(8):2389-2400. PubMed ID: 33507343
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer-derived GM-CSF regulates arginase 1 in myeloid cells to promote an immunosuppressive microenvironment.
Su X; Xu Y; Fox GC; Xiang J; Kwakwa KA; Davis JL; Belle JI; Lee WC; Wong WH; Fontana F; Hernandez-Aya LF; Kobayashi T; Tomasson HM; Su J; Bakewell SJ; Stewart SA; Egbulefu C; Karmakar P; Meyer MA; Veis DJ; DeNardo DG; Lanza GM; Achilefu S; Weilbaecher KN
J Clin Invest; 2021 Oct; 131(20):. PubMed ID: 34520398
[TBL] [Abstract][Full Text] [Related]
13. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes.
Rodriguez PC; Ernstoff MS; Hernandez C; Atkins M; Zabaleta J; Sierra R; Ochoa AC
Cancer Res; 2009 Feb; 69(4):1553-60. PubMed ID: 19201693
[TBL] [Abstract][Full Text] [Related]
14. Myeloid Cell-Derived Arginase in Cancer Immune Response.
Grzywa TM; Sosnowska A; Matryba P; Rydzynska Z; Jasinski M; Nowis D; Golab J
Front Immunol; 2020; 11():938. PubMed ID: 32499785
[TBL] [Abstract][Full Text] [Related]
15. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
[TBL] [Abstract][Full Text] [Related]
16. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
17. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
Lee JW; Zhang Y; Eoh KJ; Sharma R; Sanmamed MF; Wu J; Choi J; Park HS; Iwasaki A; Kaftan E; Chen L; Papadimitrakopoulou V; Herbst RS; Koo JS
J Thorac Oncol; 2019 Jun; 14(6):1046-1060. PubMed ID: 30771521
[TBL] [Abstract][Full Text] [Related]
18. Tumor Cells Modulate Macrophage Phenotype in a Novel In Vitro Co-Culture Model of the NSCLC Tumor Microenvironment.
Park JV; Chandra R; Cai L; Ganguly D; Li H; Toombs JE; Girard L; Brekken RA; Minna JD
J Thorac Oncol; 2022 Oct; 17(10):1178-1191. PubMed ID: 35798240
[TBL] [Abstract][Full Text] [Related]
19. E3 ligase TRIM28 promotes anti-PD-1 resistance in non-small cell lung cancer by enhancing the recruitment of myeloid-derived suppressor cells.
Liang M; Sun Z; Chen X; Wang L; Wang H; Qin L; Zhao W; Geng B
J Exp Clin Cancer Res; 2023 Oct; 42(1):275. PubMed ID: 37865804
[TBL] [Abstract][Full Text] [Related]
20. Arginase 1-Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti-PD-1 Checkpoint Blockade.
Aaboe Jørgensen M; Ugel S; Linder Hübbe M; Carretta M; Perez-Penco M; Weis-Banke SE; Martinenaite E; Kopp K; Chapellier M; Adamo A; De Sanctis F; Frusteri C; Iezzi M; Zocca MB; Hargbøll Madsen D; Wakatsuki Pedersen A; Bronte V; Andersen MH
Cancer Immunol Res; 2021 Nov; 9(11):1316-1326. PubMed ID: 34518197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
